Literature DB >> 29759615

Enhancing Response in the Cardiac Resynchronization Therapy Patient: The 3B Perspective-Bench, Bits, and Bedside.

Angelo Auricchio1, Frits W Prinzen2.   

Abstract

Cardiac resynchronization therapy (CRT) is an established nonpharmacological treatment for patients with heart failure (HF), reduced left ventricular (LV) ejection fraction, and a wide QRS complex. Although the therapy was developed 30 years ago and approved by the Food and Drug Administration in 2001, attempts to improve it have never stopped. Such improvements have been facilitated by combining knowledge from bench (basic science), bits (computer modeling), and bedside (clinical studies); these issues are addressed in the present review. Improvements include better patient selection, positioning of the LV lead, pacing from multiple sites, and optimization of atrioventricular and ventriculo-ventricular intervals. Overall, patterns of electrocardiographic and echocardiographic (strain) signals appear to be more useful for patient selection than timing intervals (QRS duration, time-to-peak shortening). Quadripolar leads have significantly improved CRT outcome due to increased electrical and mechanical lead performance (avoiding phrenic nerve stimulation and improving lead stability), but also thanks to the flexibility offered by the novel leads to avoid in-scar pacing. The benefit of multiple site stimulation over optimal conventional biventricular pacing seems small and is awaiting evidence from large trials. There is rapidly growing interest in merging imaging information to guide positioning of the LV lead in late activated regions without scar and in LV lead positions other than the epicardial coronary veins (LV endocardium, His bundle, LV septum). All these developments look promising but await further clinical validation. Finally, computer modeling is rapidly becoming important in understanding the substrate for CRT, in improving and assisting patient selection, as well as in guiding therapy planning.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac magnetic resonance; cardiac resynchronization therapy; left bundle branch block; outcome; pacing

Mesh:

Year:  2017        PMID: 29759615     DOI: 10.1016/j.jacep.2017.08.005

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  6 in total

Review 1.  [Multipoint pacing-more CRT or a waste of battery power?]

Authors:  J Müller-Leisse; C Zormpas; T König; D Duncker; C Veltmann
Journal:  Herz       Date:  2018-11       Impact factor: 1.443

Review 2.  Resynchronization Therapy for Patients with Congenital Heart Disease: Are We Ready for Prime Time?

Authors:  Scott Anjewierden; Peter F Aziz
Journal:  Curr Cardiol Rep       Date:  2018-07-18       Impact factor: 2.931

3.  Managing Cardiac Resynchronization Therapy Nonresponse: Conventional and Unconventional Techniques.

Authors:  Richard G Trohman; Henry D Huang; Ryan M Zimberg; Nicholas J Serafini; Parikshit S Sharma
Journal:  J Innov Card Rhythm Manag       Date:  2018-11-15

4.  Machine Learning Prediction of Cardiac Resynchronisation Therapy Response From Combination of Clinical and Model-Driven Data.

Authors:  Svyatoslav Khamzin; Arsenii Dokuchaev; Anastasia Bazhutina; Tatiana Chumarnaya; Stepan Zubarev; Tamara Lyubimtseva; Viktoria Lebedeva; Dmitry Lebedev; Viatcheslav Gurev; Olga Solovyova
Journal:  Front Physiol       Date:  2021-12-14       Impact factor: 4.566

Review 5.  Computational models in cardiology.

Authors:  Steven A Niederer; Joost Lumens; Natalia A Trayanova
Journal:  Nat Rev Cardiol       Date:  2019-02       Impact factor: 32.419

6.  Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias.

Authors:  Osita Okafor; Abbasin Zegard; Peter van Dam; Berthold Stegemann; Tian Qiu; Howard Marshall; Francisco Leyva
Journal:  J Am Heart Assoc       Date:  2019-10-28       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.